Auriga Reiterates Buy on Myriad Genetics (MYGN)
A number of other analysts have also recently weighed in on MYGN. Analysts at Oppenheimer (NYSE: OPY) raised their price target on shares of Myriad Genetics to $29.00 in a research note to investors on Wednesday. They now have a “market perform” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of Myriad Genetics from $27.00 to $29.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Cowen upgraded shares of Myriad Genetics from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, April 20th.
Myriad Genetics traded up 0.19% on Wednesday, hitting $26.50. Myriad Genetics has a 1-year low of $17.51 and a 1-year high of $27.00. The company has a market cap of $2.234 billion and a price-to-earnings ratio of 21.63.
The company last announced its quarterly results on Tuesday, May 1st. It reported $0.34 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.32 EPS by $0.02. The company’s quarterly revenue was up 26.8% on a year-over-year basis. Analysts expect that Myriad Genetics will post $0.33 EPS next quarter.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests.